• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

新型5-氨基-2-(苄基硫代)噻唑-4-甲酰胺类化合物的设计、合成及抗肿瘤活性

王璐, 尤启冬, 姜正羽

王璐, 尤启冬, 姜正羽. 新型5-氨基-2-(苄基硫代)噻唑-4-甲酰胺类化合物的设计、合成及抗肿瘤活性[J]. 中国药科大学学报, 2017, 48(1): 16-22. DOI: 10.11665/j.issn.1000-5048.20170103
引用本文: 王璐, 尤启冬, 姜正羽. 新型5-氨基-2-(苄基硫代)噻唑-4-甲酰胺类化合物的设计、合成及抗肿瘤活性[J]. 中国药科大学学报, 2017, 48(1): 16-22. DOI: 10.11665/j.issn.1000-5048.20170103
shu
WANG Lu, YOU Qidong, JIANG Zhengyu. Design, synthesis and anti-tumor activity of novel 5-amino-2-(benzylthio)thiazole-4-carboxamide derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(1): 16-22. DOI: 10.11665/j.issn.1000-5048.20170103
Citation: WANG Lu, YOU Qidong, JIANG Zhengyu. Design, synthesis and anti-tumor activity of novel 5-amino-2-(benzylthio)thiazole-4-carboxamide derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(1): 16-22. DOI: 10.11665/j.issn.1000-5048.20170103
shu

新型5-氨基-2-(苄基硫代)噻唑-4-甲酰胺类化合物的设计、合成及抗肿瘤活性

  • 1.

    中国药科大学江苏省药物分子设计与成药性优化重点实验室

  • 2.

    中国药科大学药物化学教研室

基金项目: 高等学校博士学科点专项科研基金资助项目(No.2013009611002)；国家“重大新药创制”科技重大专项资助项目(No.2013ZX09402102)

Design, synthesis and anti-tumor activity of novel 5-amino-2-(benzylthio)thiazole-4-carboxamide derivatives

摘要

    摘要
  • 摘要: 为了寻找具有更好抗肿瘤活性的化合物，设计合成了一系列5-氨基-2-(苄基硫代)噻唑-4-甲酰胺衍生物。以2-氨基-2-氰基-乙酰胺为起始原料，合成了16个化合物 DDO-5401 ~ DDO-5416 ；目标化合物结构经IR、1H NMR和ESI-MS确证；采用MTT法对目标化合物进行5株肿瘤细胞(HCT116、HepG2、A549、MDA-MB-231、MCF-7)体外抗肿瘤活性测定。合成的化合物对肿瘤细胞尤其是A549细胞表现出了良好的抑制活性；构效关系研究表明，苯环上连有给电子基团的化合物抑制活性要好于连有吸电子基团的化合物。化合物 DDO-5413 的抑制活性最强，对乳腺癌细胞MDA-MB-231和MCF-7抑制活性好于阳性对照药达沙替尼，值得进一步研究。
    Abstract: A series of 5-amino-2-(benzylthio)thiazole-4-carboxamide derivatives were designed and synthesized to discover novel compounds with anti-tumor activity. Compounds DDO-5401 - DDO-5416 were synthesized using 2-amino-2-cyanoacetamide as the start material. The structures of the synthesized compounds were confirmed by IR, 1H NMR and ESI-MS. The in vitro anti-tumor activities of the synthesized compounds were determined by MTT assay in HCT116, HepG2, A549, MDA-MB-231 and MCF-7 cell lines. Target compounds showed good anti-tumor activity especially in A549 cell line. SAR study showed that electron donating groups were more favorable than electron absorption ones. Compound DDO-5413 exhibited noteworthy activity in MDA-MB-231 and MCF-7 cell lines with IC50 value lower than the positive reference dasatinib. It suggested that DDO-5413 might be the candidate for further investigation.
    • HTML全文
    • 参考文献(11)
  • [1] Long PH.The clinical use of sulfanilamide,sulfapyridine,sulfathiazole,sulfaguanidine,and sulfadiazine in the prophylaxis and treatment of infections[J].Can Med Assoc J,1941,44(3):217-227.
    [2] Wang S,Wu B,Xue J,et al.Nizatidine,a small molecular compound,enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge[J].Hum Vaccin Immunother,2014,10(2):461-468.
    [3] Obach RS,Kalgutkar AS,Ryder TF,et al.In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam:insights into the hepatotoxicity of sudoxicam[J].Chem Res Toxicol,2008,21(9):1890-1899.
    [4] Molina JM,Clotet B,van Lunzen J,et al.Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection(FLAMINGO):96 week results from a randomised,open-label,phase 3b study[J].Lancet HIV,2015,2(4):e127-136.
    [5] Adelroth E,Inman MD,Summers E,et al.Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast[J].J Allergy Clin Immunol,1997,99(2):210-215.
    [6] Becker MA,Schumacher HR Jr,Wortmann RL,et al.Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phase II,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis Rheum,2005,52(3):916-923.
    [7] Latagliata R,Breccia M,Castagnetti F,et al.Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib[J].Leuk Res,2011,35(9):1164-1169.
    [8] Cocorocchio E,Gandini S,Alfieri S,et al.Dabrafenib in metastatic melanoma:a monocentric ‘real life’ experience[J].Ecancermedicalscience,2016,10:624.
    [9] Rivera E,Gomez H.Chemotherapy resistance in metastatic breast cancer:the evolving role of ixabepilone[J].Breast Cancer Res,2010,12(2):S2.
    [10] Wang J,Guo J,Tang Y,et al.Short and efficient synthesis of 5-aminothiazole-4-carboxamide[J].Heterocycl Commun,2014,20(3):175-176.
    [11] Liu Y,Wang TT,Chen L.Synthesis and antitumor activity of isosteviol derivatives[J].J China Pharm Univ(中国药科大学学报),2015,46(1):16-27.
    • 相关文章
    • 施引文献(11)

  • 期刊类型引用(9)

    1. 戴建英. 在体单向肠灌流法研究知母提取物肠吸收特性. 湖北医药学院学报. 2024(05): 518-523 . 百度学术
    2. 黄秋妹，石茗，王珍，倪明龙，阙慧卿. 吴茱萸碱制剂的研究进展. 广东化工. 2023(10): 66-68+79 . 百度学术
    3. 黄秋妹，阙慧卿，李唯，钱丽萍，刘经亮. 吴茱萸碱脂质体的制备工艺研究. 医学信息. 2023(19): 19-22 . 百度学术
    4. 张佩琛，方栋，郝海军. 吴茱萸碱胃漂浮片制备及其对家兔胃黏膜损伤的保护作用. 中成药. 2023(11): 3527-3533 . 百度学术
    5. 董丹丹，焦红军，郝海军，范明松. 吴茱萸碱纳米结构脂质载体处方优化和SD大鼠体内口服药动学研究. 中草药. 2022(01): 60-70 . 百度学术
    6. 宋朔尧，杨贵前，陶玲，沈祥春，张环，李和蓉，王守莉，石惠云，刘文. 吴茱萸碱磷脂复合物自乳化药物递送系统的制备、表征及胃黏膜渗透性研究. 中国药房. 2022(09): 1056-1061 . 百度学术
    7. 赵梦，刘卓雅，于嘉敏，王芮，范铭婕，乔宏志. 生姜细胞外囊泡样纳米粒载吴茱萸碱的处方工艺及体外释药研究. 南京中医药大学学报. 2022(06): 527-533 . 百度学术
    8. 决利利，梁婧，李晓婷，王柯静，周珊珊，刘艳菊. 松果菊苷固体脂质纳米粒的制备及其在体肠吸收特性、体内药动学研究. 中成药. 2022(08): 2429-2434 . 百度学术
    9. 陈云，曾梅，徐靖鑫，胡娟，张景勍. 二甲双胍-白藜芦醇复合物油包水型纳米乳在体肠吸收及其药代动力学研究. 中国药科大学学报. 2021(03): 325-331 . 本站查看

    其他类型引用(2)

    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 11
出版历程
  • 刊出日期:  2017-02-24

目录

摘要
HTML全文
    参考文献(11)
    相关文章
    施引文献(11)
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：400400

    x 关闭 永久关闭